Gene · 6241
Papers4,414
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 4,414
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RETRACTION: Long Noncoding RNA LINC00958 Regulates Cell Sensitivity to Radiotherapy Through RRM2 by Binding to microRNA-5095 in Cervical Cancer. | J Cell Physiol | 2025 | 39801448 | PubTator, text mining | PubMed |
| The miRNA-mRNA Regulatory Network in Human Hepatocellular Carcinoma by Transcriptomic Analysis From GEO. | Cancer Rep (Hoboken) | 2025 | 39764737 | PubTator, text mining | PubMed |
| Silencing circ_0043256 inhibited CoCl2-induced proliferation, migration, and aerobic glycolysis in gastric cancer cells. | Sci Rep | 2025 | 39748101 | PubTator, text mining | PubMed |
| Super-enhancer-associated circPVT1 promotes malignancy of hepatocellular carcinoma via YBX1-mediated RRM2 activation. | Cancer Lett | 2025 | 39694225 | PubTator, text mining | PubMed |
| RRM2 Is a Putative Biomarker and Promotes Bladder Cancer Progression via PI3K/AKT/mTOR Pathway. | J Cell Physiol | 2025 | 39676643 | PubTator, text mining | PubMed |
| Resveratrol promotes mitophagy via the MALAT1/miR-143-3p/RRM2 axis and suppresses cancer progression in hepatocellular carcinoma. | J Integr Med | 2025 | 39675939 | PubTator, text mining | PubMed |
| Search for germline gene variants in colorectal cancer families presenting with multiple primary colorectal cancers. | Int J Cancer | 2025 | 39654522 | PubTator, text mining | PubMed |
| SSBP1 positively regulates RRM2, affecting epithelial mesenchymal transition and cell cycle arrest in human lung adenocarcinoma cells. | Cell Signal | 2025 | 39643024 | PubTator, text mining | PubMed |
| Statistical modeling of single-cell epitranscriptomics enabled trajectory and regulatory inference of RNA methylation. | Cell Genom | 2025 | 39642887 | PubTator, text mining | PubMed |
| Design, Screening and Development of Asymmetric siRNAs Targeting the MYC Oncogene in Triple-Negative Breast Cancer. | Biomol Ther (Seoul) | 2025 | 39632755 | PubTator, text mining | PubMed |
| Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer. | Transl Oncol | 2025 | 39631207 | PubTator, text mining | PubMed |
| FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner. | Mol Cell Biochem | 2025 | 39630361 | PubTator, text mining | PubMed |
| Revealing multi-level shortrange migration of electrons on full-spectrum response e-LDH/t-BiOCl/Bi2S3 and their essential role in the detoxification of Cr(VI) and refractory organic pollutants. | Environ Res | 2025 | 39617156 | PubTator, text mining | PubMed |
| Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma. | Curr Med Chem | 2025 | 39248068 | PubTator, text mining | PubMed |
| Significance of Ribonucleoside-diphosphate Reductase Subunit M2 in Lung Adenocarcinoma. | Curr Gene Ther | 2025 | 38920074 | PubTator, text mining | PubMed |
| The potential of ribonucleotide reductase M2 as a novel prognostic maker and therapeutic target to inhibit medulloblastoma proliferation, migration, and invasiveness. | Pediatr Discov | 2024 | 40625451 | PubTator, text mining | PubMed |
| Identifying ribonucleotide reductase subunit genes as potential lung adenocarcinomas biomarkers using integrated bioinformatics analysis. | Malawi Med J | 2024 | 40191558 | PubTator, text mining | PubMed |
| hnRNPH1 Inhibits Influenza Virus Replication by Binding Viral RNA. | Microorganisms | 2024 | 39858792 | PubTator, text mining | PubMed |
| Synergistic machine learning models utilizing ferroptosis-related genes for improved neuroblastoma outcome prediction. | Transl Pediatr | 2024 | 39822999 | PubTator, text mining | PubMed |
| The bioinformatics analysis and experimental validation of the carcinogenic role of EXO1 in lung adenocarcinoma. | Front Oncol | 2024 | 39777332 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6241/papers?page=12